Effect of ouabain on myocardial remodeling in rats

YANPING REN¹, MINGJUAN ZHANG², TING ZHANG¹ and RUOWEN HUANG¹

¹Geriatric-Cardiovascular Department, The First Affiliated Hospital, Medical College of Xi’an Jiaotong University, Xi’an, Shaanxi 710061; ²Cardiovascular Department, The Second Affiliated Hospital, Medical College of Xi’an Jiaotong University, Xi’an, Shaanxi 710003, P.R. China

Received January 25, 2013; Accepted April 3, 2013

DOI: 10.3892/etm.2013.1098

Abstract. The aim of this study was to investigate the effect of ouabain (EO) on myocardial remodeling. Twenty-two adult male Sprague-Dawley rats were randomly divided into two groups: the rats in the EO group (n=12) were intraperitoneally injected with EO daily and those in the control group (n=10) were injected with physiological saline daily. After 8 weeks the rats were sacrificed. The ultrastructural changes in the myocardium were observed. The expression levels of voltage-gated potassium channel 4.2 (Kᵥ4.2) were detected by real-time quantitative reverse transcription-polymerase chain reaction. The effects of EO on the myocardial action potential and transient potassium efflux (Iᵥ transient) were measured by patch clamping. The systolic blood pressure (SBP) of 10 of the 12 rats in the EO group, designated as the EO-sensitive (OS) rats, began to increase from the fifth week of treatment and was significantly higher compared with that of the control group 6 weeks later (P<0.01). The remaining 2 rats in the EO group that presented no increase in SBP following 8 weeks of treatment (P>0.05) were designated as EO-resistant (OR) rats. Pathological ultrastructural changes were significant in the apical mid-myocardium of the OS rats. No significant differences in Kᵥ4.2 expression were observed among the OS, OR and control rats. The patch clamp results revealed that EO prolongs the action potential duration, reduces Iᵥ transient and triggers the electrical remodeling of the myocardium. EO induces a blood pressure increase and triggers structural and electrical remodeling.

Introduction

Sodium/potassium pump inhibitors in human plasma are identical or similar in structure to plant-derived ouabain (EO) and are synthesized by the adrenal cortex (1). Since Hamlyn et al confirmed that EO was an endogenous sodium pump inhibitor in 1991 (2), it has been gradually elucidated as an important factor that participates in the pathogenesis of hypertension in the neuroendocrine network. The persistent and specific association of EO with hypertension indicates that 40-50% of patients with mild to moderate primary hypertension have elevated EO, with normal dietary salt intakes (3-6). Evidence indicates that EO does not fulfill the criteria for a putative natriuretic hormone; however, it is essential in the adaptation to sodium depletion and sodium loading (7). Several lines of experimental evidence clearly demonstrate the prohypertensive role of EO, including induction of hypertension in EO-treated rodents, elevation of EO levels in hypertensive rats and observations of the central prohypertensive action of this hormone. Three mechanisms for the prohypertensive effect, including the ‘adducin paradigm’, the existence of highly sensitive EO-binding sites in vascular smooth muscle and central effects, were proposed to link EO to vasoconstriction in hypertension (8). Chronic EO treatment produces hypertension, which depends on the activation of central nervous mechanisms associated with increased sympathetic tone, subsequent to the activation of the brain renin-angiotensin (9) and endothelin systems (10), as well as peripheral vascular mechanisms (11). In addition, vascular endothelial cells, whose functional integrity is crucial for the maintenance of blood flow and antithrombotic activity, may be a target for endogenous EO. We previously studied the effect of EO on human umbilical vein endothelial cells (HUVECs) and identified that EO stimulates the proliferation of HUVECs at physiological concentrations (0.3-0.9 nmol/l). However, cell death was induced at pathological concentrations (0.9-1.8 nmol/l), including the swelling phenomenon and the appearance of apoptotic bodies (12). Based on our previous study, the effects of EO on endothelial dysfunction and cardiac remodeling were investigated in EO-sensitive (OS) hypertensive rats.

Materials and methods

Animal model. A total of 22 adult male Sprague-Dawley rats, weighing 180-250 g, SPF grade, were provided by the
Laboratory Animal Center of Xi’an Jiaotong University College of Medicine. The local legislation for ethics on experiments on animals and guidelines for the care and use of laboratory animals (from the Ethics Committee of Xi’an Jiaotong University) were followed in all animal procedures. All animals were allowed time to adapt to the laboratory environment with free access to food and water in temperature- and humidity-controlled housing with natural illumination for a week and subsequently fasted for 12 h prior to the experiment. The animals were randomly divided into two groups: the EO group (O group, n=12) and the control group (N group, n=10). The O group was treated with 20 µg/kg/day EO by intraperitoneal injection for 8 weeks. The N group was treated with 1 ml/kg/day normal saline by intraperitoneal injection for 8 weeks. Weight and systolic blood pressure (SBP) were recorded three times for one week and the mean values were calculated. SBP was measured via an indirect tail cuff method using a blood pressure recorder for rats (RBP-1B; China-Japan Clinical Medicine Institute, Beijing, China). After 6 weeks, the O group was divided into two groups based on their recorded BP: the OS group (BP increased, n=10) and the EO-resistant OR group (no clear increase in BP, n=2).

Separation of rat ventricular myocytes. Before isolation, the solutions were saturated with O₂ for 30 min. The rats were anesthetized with a bolus dose of 20% urethane (6 ml/kg) and fixed on the surgery table. The heart was exposed by rapid thoracotomy, removed and slightly modified in cold (4°C) calcium-free solution. The aorta was fixed to the heart tube of a Langendorff perfusion device with a surgical suture. Then, the isolated heart was perfused for 6 min through the aorta with calcium-free solution and then for 8-12 min with a calcium-free buffer containing 50 µM Ca²⁺, 0.33 g/l collagenase and 0.5 mg/ml bovine serum albumin. The digestion was terminated when the heart became soft and enlarged, followed by washing for 5 min. The entire process was performed while maintaining the perfusion pressure at ~70 cm at 37°C. Following perfusion, the separated ventricles were cut into small pieces, incubated in a fresh calcium-free solution and mechanically dispersed using a large-bore fire-polished Pasteur pipette. Single intact cells were separated by filtration. Recalcification of the isolated cells was performed using 0.1 mM Ca²⁺ per 10 min to a final calcium concentration of 0.8 mM.

Recording action potentials (APs) and transient outward potassium current (Iₒ). Only quiescent rod-shaped cells that presented clear cross-striations were selected. All recordings were obtained at room temperature (22-25°C). A small aliquot tracephoresis, cDNA was synthesized using M-MLV reverse transcriptase according to the instructions of the manufacturer (Takara Bio Inc.). All cDNA samples were used immediately or stored at -20°C until analysis.

Primers and probes were designed and synthesized by Sangon Biotechnology Co., Ltd. (Shanghai, China). Glyceraldehyde-3-phosphate dehydrogenase was used as the control. The primer and probe sequences are listed in Table I.

The K_4.2 mRNA expression levels in the rat myocardial tissue in the different groups were detected by RT-PCR. The reaction mixture contained 1 µl each forward and reverse primers, 1 µl fluorescent probe, 1 µl RT/platinum® Taq mix and 4 µl RNA template. Diethylpyrocarbonate (DEPC)-treated triple-distilled water was added to a final volume of 50 µl. The PCR program was as follows: reverse transcription at 48°C for 45 min; 94°C for 5 min; then 35 cycles of 94°C for 30 sec, 56°C for 30 sec, 72°C for 30 sec, and a final extension at 72°C for 5 min. The PCR products were identified by 1.5% agarose gel electrophoresis.

| Gene          | Primer sequence                                                                 |
|---------------|---------------------------------------------------------------------------------|
| K_4.2 Forward: 5-GCCTTCGTTAGAAATCTGGATC-3       | Primer sequence                                                                 |
| K_4.2 Reverse: 5-CACTTCATGCGCTTCTTCAA-3          |                                                                                   |
| K_4.2 Probe: 5-FAM-CGAGACAACACCACCACCTGCTTCACTA-MRA-3 |                                                                                   |
| GAPDH Forward: 5-TGGTCCTACATGTTCCAGTATGACT-3      |                                                                                   |
| GAPDH Reverse: 5-CTTTCGTTACGCGGAGTCTC-3           |                                                                                   |
| GAPDH Probe: 5-FAM-ACGGCAAGTTCAACCGGCACGTCAATA-MRA-3 |                                                                                   |

K_4.2, voltage-gated potassium channel 4.2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
(~1.5 ml) of the solution containing the isolated cells was placed in an open perfusion chamber mounted on the stage of an inverted microscope. Cardiac myocytes were allowed to adhere to the bottom of the chamber for 8 min and were then perfused at 1.5 ml/min with Tyrode’s solution. The capacitance and series resistance compensation were optimized; 60-80% compensation was usually obtained. The potential compensation was ~2 mV. The whole-cell configuration of the patch-clamp technique was used to record APs in the current-clamp mode. APs were elicited by stimulation (square wave, 10 msec duration, 100-120% excitation threshold current, 600 pA and 0 mV constant voltage). I_{in} was evoked by depolarizing pulses from a holding potential of -80 mV to voltage steps from -40 to +60 mV in 10 mV increments for 250 msec. The calcium current was blocked by adding 0.1 mM CdCl_2 to Tyrode’s solution. A prestep of 30 msec to -40 mV was used to inactivate sodium currents. The inactivation of I_{in} was measured after a 400 msec conditioning prepulse at 0.2 stimulation frequency from a holding potential of -80 mV to potentials between -40 and +40 mV (in 10 mV steps), followed by a 250 msec depolarizing pulse to +40 mV at 0.5 stimulation frequency.

**Statistical analysis.** SPSS 10.0 (SPSS, Inc., Chicago, IL, USA) was used to analyze the data. All values are expressed as mean ± standard deviation (SD). The significance of differences among groups was determined by single factor analysis of variance (ANOVA). The least significant difference test was applied for multiple comparisons between groups. A t-test was used to compare the significant differences between the pre- and post-experiments. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Changes of rat SBP.** The effects of the continued infusion of EO on the SBP in the first 4 weeks were examined. The SBP of all rats slightly increased and was accompanied by increased weight. However, no significant differences were observed between the O and N groups. During the fifth week, the SBP of 10 of the 12 rats in the O group began to increase. After 6 weeks, the SBP of the 10 rats was significantly higher compared with that in the N group, in which the rats received normal saline (138.2±8.0 vs. 120.1±5.2 mmHg; P<0.01). The 10 rats were designated as the OS rats. The remaining two rats in the O group, with normal SBP after 8 weeks of treatment (126.7±11.4 vs. 125.4±6.9 mmHg; P>0.05) were designated as the OR rats (Fig. 1).

**Ultrastructural changes in the rat myocardium.** The pathological changes in the left ventricular apical mid-myocardium of the OS rats were observed under electron microscopy. The cardiac mitochondria were hyperplastic, hypertrophic and swollen (Fig. 2A). The microvascular membrane permeability in myocardial tissue and exudation around the vessels increased in the OS rats (Fig. 2B). Collagen fibers proliferated among myocardial cells (Fig. 2C). The connections of the intercalated discs between adjacent myocardial cells were unclear in the OS rats (Fig. 2D). There was no significant difference between the ultrastructural changes in the myocardium of rats in the OR and N groups (Fig. 2E).

The left ventricular myocytes in the N group were regularly arranged. The morphology of the myocardial cells was intact. The thick and thin myofilaments were regularly arranged. Uniformly sized, oval mitochondria were abundant. Sarcomeres solution was 3.5 mΩ. The capacitance and series resistance compensation were optimized; 60-80% compensation was usually obtained. The potential compensation was ~2 mV. The whole-cell configuration of the patch-clamp technique was used to record APs in the current-clamp mode. APs were elicited by stimulation (square wave, 10 msec duration, 100-120% excitation threshold current, 600 pA and 0 mV constant voltage). I_{in} was evoked by depolarizing pulses from a holding potential of -80 mV to voltage steps from -40 to +60 mV in 10 mV increments for 250 msec. The calcium current was blocked by adding 0.1 mM CdCl_2 to Tyrode’s solution. A prestep of 30 msec to -40 mV was used to inactivate sodium currents. The inactivation of I_{in} was measured after a 400 msec conditioning prepulse at 0.2 stimulation frequency from a holding potential of -80 mV to potentials between -40 and +40 mV (in 10 mV steps), followed by a 250 msec depolarizing pulse to +40 mV at 0.5 stimulation frequency.

**Statistical analysis.** SPSS 10.0 (SPSS, Inc., Chicago, IL, USA) was used to analyze the data. All values are expressed as mean ± standard deviation (SD). The significance of differences among groups was determined by single factor analysis of variance (ANOVA). The least significant difference test was applied for multiple comparisons between groups. A t-test was used to compare the significant differences between the pre- and post-experiments. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Changes of rat SBP.** The effects of the continued infusion of EO on the SBP in the first 4 weeks were examined. The SBP of all rats slightly increased and was accompanied by increased weight. However, no significant differences were observed between the O and N groups. During the fifth week, the SBP of 10 of the 12 rats in the O group began to increase. After 6 weeks, the SBP of the 10 rats was significantly higher compared with that in the N group, in which the rats received normal saline (138.2±8.0 vs. 120.1±5.2 mmHg; P<0.01). The 10 rats were designated as the OS rats. The remaining two rats in the O group, with normal SBP after 8 weeks of treatment (126.7±11.4 vs. 125.4±6.9 mmHg; P>0.05) were designated as the OR rats (Fig. 1).

**Ultrastructural changes in the rat myocardium.** The pathological changes in the left ventricular apical mid-myocardium of the OS rats were observed under electron microscopy. The cardiac mitochondria were hyperplastic, hypertrophic and swollen (Fig. 2A). The microvascular membrane permeability in myocardial tissue and exudation around the vessels increased (Fig. 2B). Collagen fibers proliferated among the myocardial cells (Fig. 2C). The connections of the intercalated discs between adjacent myocardial cells were unclear (Fig. 2D). There was no significant difference between the ultrastructural changes in the myocardium of rats in the OR and N groups (Fig. 2E).

The left ventricular myocytes in the N group were regularly arranged. The morphology of the myocardial cells was intact. The thick and thin myofilaments were regularly arranged. Uniformly sized, oval mitochondria were abundant. Sarcomeres
and light-dark bands were clearly visible. The pericellular membrane was uninterrupted and intact. There was a small amount of collagen fibers among the myocardial cells (Fig. 2F).

**Kv4.2 expression.** There were no significant differences between the Kv4.2 expression levels in the myocardial cells of the OS (51,345±10,230), OR (53,000±9,880) and control rats (49,878±12,540) (P>0.05).

**APs and Ito.** APs were recorded under the whole-cell current clamp configuration in rat ventricular myocytes. The AP duration (APD) of the cardiomyocytes was prolonged after they were perfused for 1 min with 1.8 nmol/l EO. The difference was statistically significant; the APD at 50% amplitude (APD_{50}) before and after perfusion was 183±21 and 252±30 msec, respectively (P<0.01). I_{to} of the current density significantly decreased (I_{to} values before and after perfusion

---

Figure 3. Changes of action potential duration (APD) of rat cardiomyocytes perfused with ouabain (cell count, n=15).

Figure 4. Changes of transient outward potassium current (I_{to}) of rat cardiomyocytes perfused with ouabain (cell count, n=15).

Figure 5. (A) Changes of rat ventricular myocyte action potentials in the ouabain-sensitive (OS), ouabain-resistant (OR) and control (N) groups. (B) Transient outward potassium current (I_{to}) changes of rat ventricular myocyte action potentials in the OS, OR and control groups.
were 2,400±231 and 183±104 pA, respectively; P<0.01; cell count, n=15; Figs. 3 and 4).

The recordings of the changes in AP and INa values of the rat ventricular myocytes in certain models and the N group indicated significant differences between the APD90 values of the OS group (242±23 msec; cell count, n=8) and N group (188±31 msec; cell count, n=12; P<0.01). No significant differences were observed between the APD90 values of the OR group (184±19 msec; cell count, n=7) and N group (188±31 msec; cell count, n=12; P>0.05). As shown in Fig. 5A and B, the INa of rat ventricular myocytes in the OS group (1,854±192 pA; cell count, n=8) was significantly increased compared with that in the control group (2,413±331 pA; cell count, n=12; P<0.01). No significant difference was observed between the INa of the OR group (2,580±231 pA; cell count, n=7) and N group (2,413±331 pA; cell count, n=12; P>0.05).

Discussion

EO, a steroid hormone, is synthesized by the hypothalamus and adrenal cortex (1). EO participates in the neuroendocrine regulation of the cardiovascular system by inhibiting the sodium pump on the cell membrane. Previous studies indicated that EO levels are closely related to blood pressure and cardiovascular complications, including heart failure in rats and humans, during early hypertension (13-16). EO also affects hemodynamics. Intravenous application of EO produced an excitatory effect on baroreceptor nerve activity that was greater in hypertensive rats (17). Exposure of rats to nanomolar concentrations of EO for a longer period of time leads to arterial hypertension (18,19) and smooth muscle proliferation (20,21). In patients with essential hypertension, the circulating endogenous EO concentration correlates directly with the relative wall thickness of the heart and the total peripheral resistance; however, it is inversely correlated with the left ventricular end-diastolic index, stroke index and cardiac index (6).

EO also causes changes in the general morphology of the left ventricle in patients with essential hypertension (6,22). In addition, several reports, including the present study, have also demonstrated that there is a correlation between EO and endothelial dysfunction (12,23,24). In the present study, certain significant pathological ultrastructural changes were also identified in rat apical mid-myocardium, in accordance with the findings of a previous study (25). We successfully constructed an experimental animal model of hypertension using intraperitoneal EO injection. The blood pressures of the majority of rats (10 out of 12 rats) increased following injection of EO. The remaining two rats in the O group that did not have increased SBP after 8 weeks of treatment were designated as OR rats. Clear pathological changes were observed in the left ventricular apical mid-myocardium of the OS rats under electron microscopy. The changes included the rupture of the aortic intima and outer membranes, as well as endothelial cell loss. Although no significant loss of the capillary endothelial cells in the myocardium was observed, microvascular membrane permeability in the myocardial tissue and exudation around the vessels increased. These pathological changes in the endothelial cells from the main artery to capillaries may lead to the weakening or disappearance of functional membrane barriers, thereby initiating the remodeling of hypertensive vessels. The structural integrity of the mitochondria is important for maintaining the cellular structure. Proliferation and swelling of the mitochondria in the myocardia were observed. The EO injection also caused structural damage to the intercalated discs between adjacent myocardial cells. The proliferation of collagen fibers among myocardial cells was also observed under electron microscopy. Myocardial fibrosis caused by increased synthesis of collagen fibers is an important pathological basis for ventricular remodeling during hypertension, resulting in systolic and diastolic dysfunction.

Previous in vitro studies suggested that the function of EO in vascular endothelial cells is related to the maintenance of reproductive metabolism in normal endothelial cells under physiological concentrations. EO at pathological concentrations may induce damage to human vascular endothelial cells, resulting in direct endothelial injury and the initiation of hypertensive vascular remodeling (1,12,13). The consequential target organ damage is also aggravated.

We investigated the effects of EO on myocardial electrical remodeling in vitro and in vivo. The results of isolated perfusion with EO and the direct study of EO in ventricular myocytes in hypertensive rats revealed that EO causes prolonged APs and reduced INa density. The results suggested that EO may cause increased blood pressure and lead to cardiac remodeling. Consequently, the proliferation of collagen fibers among myocardial cells, mitochondrial proliferation and swelling in myocardial cells, as well as the deposition of glycogen were observed under electron microscopy. However, EO may also lead to myocardial electrical remodeling due to the direct effect on myocardial electrophysiology, resulting in prolonged APs and decreased INa density. Previous studies demonstrated that a number of pathological conditions, including myocardial ischemia, stress overloading, neurohumoral factors and heart failure, lead to reduced INa density and cardiac electrical remodeling (26-29). In the present study, the results of real-time RT-PCR indicated no significant difference in Ks4,2 expression levels in the ventricular tissues of the three groups of animal models. This finding suggests that, although there was no significant difference among the transcriptional levels of the three groups, the slightly varied levels may be caused by discrepancies in the translation and functional protein levels due to certain factors. The specific mechanism remains unclear.

In view of this, and in line with our previous findings, it is possible that EO may participate in the cardiac structural and electrical remodeling of hypertension (30,31). Therefore, a significant neuroendocrine hormone, such as EO, may be used as a target for the clinical treatment of hypertension to reduce blood pressure and myocardial remodeling (16).

References

1. Boulanger BR, Lilly MP, Hamlyn JM, Laredo JM, Shurtleff D and Gann DS: Ouabain is secreted by the adrenal gland in awake dogs. Am J Physiol 264: E413-E419, 1993.
2. Hamlyn JM, Blaustein MP, Bova S, et al: Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 88: 6259-6263, 1991.
3. Manunta P, Messaggio E, Ballabeni C, et al: Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38: 198-203, 2001.
4. Manunta P, Ferrandi M, Bianchi G and Hamlyn JM: Endogenous ouabain in cardiovascular function and disease. J Hypertens 27: 9-18, 2009.
5. Manunta P, Stella P, Rivera R, et al: Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 34: 450-456, 1999.
6. Pierdomenico SD, Bucca A, Manunta P, et al: Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am J Hypertens 14: 44-50, 2001.
7. Balzan S, Nicolini G, Iervasi A, Diccecco P and Fommei E: Endogenous ouabain and acute salt loading in low-renin hypertension. Am J Hypertens 18: 906-909, 2005.
8. Bagrov AY, Shapiro JI and Fedorova OV: Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 61: 9-38, 2009.
9. Huang BS and Leenen FH: Brain renin-angiotensin system and ouabain-induced sympathetic hyperactivity and hypertension in Wistar rats. Hypertension 34: 107-112, 1999.
10. Di Filippo C, Filippelli A, Rinaldi B, et al: Chronic peripheral ouabain treatment affects the brain endothelin system of rats. J Hypertens 21: 747-753, 2003.
11. Xavier FE, Yogi A, Callera GE, et al: Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain. Br J Pharmacol 143: 794-802, 2004.
12. Ren YP, Huang RW and Lü ZR: Ouabain at pathological concentration might induce damage in human vascular endothelial cells. Acta Pharmacol Sin 27: 165-172, 2006.
13. Huang BS, Huang X, Harmse N and Leenen FH: Chronic central versus peripheral ouabain, blood pressure, and sympathetic activity in rats. Hypertension 23: 1087-1090, 1994.
14. Kimura K, Manunta P, Hamilton BP and Hamlyn JM: Different effects of in vivo ouabain and digoxin on renal artery function and blood pressure in the rat. Hypertens Res 23: S67-S76, 2000.
15. Ferrari P: Kostafuroxin: an ouabain-inhibitor countering specific forms of hypertension. Biochim Biophys Acta 1802: 1254-1258, 2010.
16. Ferrari P, Ferrandi M, Valentini G, Manunta P and Bianchi G: Targeting ouabain- and adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach. Med Hypotheses 68: 1307-1314, 2007.
17. Abreu GR, Futuro Neto HA, Cabral AM and Vasquez EC: Ouabain produces diverse excitatory effects on afferent baroreceptor nerve activity in SHR and WKY animals. Clin Exp Hypertens 20: 85-94, 1998.
18. Manunta P, Hamilton J, Rogowski AC, Hamilton BP and Hamlyn JM: Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin. Hypertens Res 23: S77-S85, 2000.
19. Yuan CM, Manunta P, Hamlyn JM, et al: Long-term ouabain administration produces hypertension in rats. Hypertension 22: 178-187, 1993.
20. Abramowitz J, Dai C, Hirschi KK, et al: Ouabain- and marinobufagenin-induced proliferation of human umbilical vein smooth muscle cells and rat vascular smooth muscle cell line, A7r5. Circulation 108: 3048-3053, 2003.
21. Aydemir-Koksoy A, Abramowitz J and Allen JC: Ouabain-induced signaling and vascular smooth muscle cell proliferation. J Biol Chem 276: 46605-46611, 2001.
22. Huang BS and Leenen FH: The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction. Curr Heart Fail Rep 6: 81-88, 2009.
23. Rossoni LV, Salaites M, Miguel M, et al: Ouabain induced hypertension is accompanied by increases in endothelial vasodilator factors. Am J Physiol Heart Circ Physiol 283: H2110-H2118, 2002.
24. Aras-López R, Blanco-Rivero J, Hernanz R, et al: Chronic ouabain treatment increases the contribution of nitric oxide to endothelium-dependent relaxation. J Physiol Biochem 64: 115-125, 2008.
25. Jiang X, Ren YP and Lv ZR: Ouabain induces cardiac remodeling in rats independent of blood pressure. Acta Pharmacol Sin 28: 344-352, 2007.
26. Volk T, Nguyen TH, Schultz JH, Faulhaber J and Ehmke H: Regional alterations of repolarizing K + currents among the left ventricular free wall of rats with ascending aortic stenosis. J Physiol 530: 443-455, 2001.
27. Singarayar S, Singleton C, Tie H, et al: Effects of components of ischemia on the Kv4.3 current stably expressed in Chinese hamster ovary cells. J Mol Cell Cardiol 34: 197-207, 2002.
28. Lukas A and Antzelevitch C: Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia. Role of the transient outward current. Circulation 88: 2903-2915, 1993.
29. Verkerk AO, Wilders R, Cornelie R, Ravesloot JH and Verheijck EE: Ionic remodeling of sinoatrial node cells by heart failure. Circulation 108: 760-766, 2003.
30. Matsumoto S, Yoshida S, Ikeda M, et al: Effects of acetazolamide on transient K + currents and action potentials in nodose ganglion neurons of adult rats. CNS Neurosci Ther 17: 66-79, 2011.
31. Matsumoto S, Kitagawa J and Takeda M: The effects of ouabain on resting membrane potential and hyperpolarization-activated current in neonatal rat nodose ganglion neurons. Neurosci Lett 439: 241-244, 2008.